Agenus Inc. buy Lector
Start price
22.03.22
/
50%
€2.54
Target price
22.03.23
-
Performance (%)
-42.13%
End price
21.05.22
€1.47
Summary
This prediction ended on 21.05.22 with a price of €1.47. The BUY prediction by Lector for Agenus Inc. performed very badly with a performance of -42.13%. Lector has 50% into this predictionAgenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Agenus Inc. | - | - | - |
| iShares Core DAX® | 0.192% | 3.121% | 16.828% |
| iShares Nasdaq 100 | 1.245% | 5.051% | 31.022% |
| iShares Nikkei 225® | -0.992% | 1.101% | 9.804% |
| iShares S&P 500 | 0.154% | 2.864% | 26.511% |
Comments by Lector for this prediction
In the thread Agenus Inc. diskutieren
Lector hat das Wertpapier Agenus Inc. in seinem Wikifolio BioTechPharma gekauft.